Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...
Veru said on Monday its experimental drug, in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...
An investigational drug from Veru helped preserve lean mass in patients taking Wegovy, though some experts raised questions ...
Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity ...
Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results ...
Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.
The scale of the decline in Veru's shares despite the positive result may reflect the amplified expectations of investors for ...
Veru said on Monday its experimental drug, in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...
In a Phase 2b trial, older patients taking Novo Nordisk’s Wegovy and Veru’s experimental drug, called enobosarm, lost on average 1.2% of lean mass after 16 weeks, compared with a 4.1% loss in ...
Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company Monday announced positive topline results from the Phase 2b ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback